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Increased cortisol metabolites and reduced activity of 11- ysis treatment [1, 2]. Despite this progress, the life expec-
hydroxysteroid dehydrogenase in patients on hemodialysis. tancy of dialysis patients is still diminished compared
Background. Patients with renal failure have symptoms as- with non-uremic subjects, and many symptoms may per-sumed to be attributable to the accumulation of toxic endo-
sist or become worse after prolonged therapy [3]. Sinceor xenobiotics. Most of these molecules, especially those with
the uremic syndrome in many aspects resembles systemica molecular weight 300 D, have not been identified. In addi-
tion to excretion, the kidney is involved in some defined meta- poisoning, the search for uremic toxins has been the
bolic processes. In the cortical collecting duct, the enzyme focus of research in the past [4–7]. Whereas molecules
11-hydroxysteroid dehydrogenase type 2 (11-HSD2) inter- with a low molecular weight have previously been identi-converts cortisol (F) and cortisone (E), and the metabolites of
fied and are efficiently cleared by hemodialysis treat-these glucocorticoids, tetrahydrocortisol (THF), 5-tetrahydro-
ment, information about larger molecules accumulatingcortisol (5-THF) and tetrahydrocortisone (THE), are excreted
in urine. We hypothesized that first, these metabolites accumu- in uremia is scarce. The identification and quantification
late and second, their concentration pattern changes in patients of larger molecules was often not possible due to techni-
on hemodialysis. cal limitations. In the present investigation we analyzedMethods. THF, 5-THF, THE, F and E were measured in
the concentrations of five glucocorticoid-related mole-plasma of 63 patients on dialysis and in 34 healthy controls by
cules in plasma and dialysate by means of GC/MS andgas-chromatography-mass spectrometry (GC/MS). In 11 pa-
tients, the metabolite clearance was determined during high observed accumulation with insufficient removal during
flux hemodialysis by using a population pharmacokinetic ap- hemodialysis treatment of three of these metabolites.
proach. The rationale for focusing on cortisol metabolites was (1)Results. Mean plasma concentrations of THF, 5-THF and
that uremic patients have signs and symptoms includingTHE were more than five times higher and those of E lower
in patients than in controls. The ratios of (THF  5-THF)/ osteopenia, abnormal body fat distribution and an en-
THE and F/E were increased in patients, indicating a reduced hanced protein catabolism that might be explained by
activity of 11-HSD2. Intradialytic clearances were between an enhanced glucocorticoid effect [8–10]. (2) Endoge-
120 and 300 mL/min and not sufficient to normalize the steroid
nous and exogenous glucocorticoids are excreted by theconcentrations.
kidney [11, 12]; (3) the kidney is an important organ forConclusion. Patients on hemodialysis exhibit pronounced
increases in THF, 5-THF and THE concentrations in plasma glucocorticoid metabolism as it converts the biologically
with insufficient removal during dialysis. Due to a reduced 11- active cortisol into its inactive form cortisone by the
HSD2 activity, an abnormal pattern of the concentrations of enzyme 11-hydroxysteroid dehydrogenase type 2 [13].
these cortisol and cortisone metabolites is observed. Since
11-hydroxysteroid dehydrogenase type 2 (11-many signs and symptoms in uremic patients resemble those
HSD2) is one of two 11-HSD enzymes that metabolizeobserved in subjects with glucocorticoid excess, the clinical
relevance of the high concentrations of these glucocorticoid 11-hydroxyglucocorticoids such as cortisol in humans
metabolites deserves further investigation. and corticosterone in rodents [reviewed in 14, 15]. 11-
HSD1 is ubiquitously expressed with highest activity in
the liver [14, 16]. In vivo it acts predominantly as a
In the past two decades long-term survival of patients reductase, but in addition possesses dehydrogenase enzy-
on hemodialysis has steadily continued to improve and matic activity in testis, brain and some other tissues (Fig.
most clinical symptoms of uremia are attenuated by dial- 1) [14]. This enzyme is localized to the endoplasmatic
reticulum membrane with the catalytic domain directed
toward the endoplasmic reticulum lumen, has a low af-Key words: hypertension, renal failure, renotoxicity, toxic endobiotics,
glucocorticoids, uremia. finity for glucocorticoids and uses nicotinamide adenine
dinucleotide phosphate (NADP) as cofactor, whereas 2002 by the International Society of Nephrology
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Fig. 1. Interconversion of cortisol/cortisone
by 11-hydroxysteroid dehydrogenase (11-
HSD) enzymes and formation of the me-
tabolites tetrahydrocortisone (THE), tetrahy-
drocortisol (THF) and 5-tetrahydrocortisol
(5-THF). A reduced activity of 11-HSD2
induces increased concentration ratios of F/E
or (5-THFTHF)/THE.
11-HSD2, which also is localized to the endoplasmic blood samples were obtained from the blood line coming
directly from the body 30, 60, 120 and 240 minutes afterreticulum membrane but with a catalytic moiety protrud-
ing into the cytoplasm, has a high affinity for glucocorti- the start of dialysis. Simultaneously with the blood sam-
ples, 200 mL of dialysate were collected from the dialy-coids and uses NAD as an obligate co-substrate [13, 16,
17]. 11-HSD1 knockout mice are resistant to hypergly- sate line immediately after the hemodialysis filter. The
dialysate and plasma samples were stored at20C untilcemia provoked by obesity or stress, but do not display
severe defects in glucocorticoid metabolism [18]. In con- analysis.
Blood samples from 12 healthy sex- and age-matchedtrast, mice lacking 11-HSD2 or with a deficiency of
11-HSD2 exhibit abnormal renal sodium retention with volunteers were analyzed in order to compare their ste-
roid levels with those of the patients before dialysis.hypertension [19]. The underlying mechanism is the ob-
servation that 11-HSD2 exclusively catalyzes the dehy- From these healthy subjects 24-hour urine collections
were obtained and the urinary excretion of steroid me-drogenation of 11-hydroxyglucocorticoids (Fig. 1) and
regulates activation of the mineralocorticoid receptor, tabolites determined for comparison with the loss of
metabolites in dialysate in uremic patients.and by these mechanisms protects cells from mineralo-
corticoid effects induced by glucocorticoids such as corti- Furthermore, morning blood samples from an addi-
tional 63 patients undergoing chronic hemodialysis weresol [20–23]. 11-HSD2 is mainly expressed in the kidney
[14, 16] and therefore one might anticipate increased taken before the dialysis session in the morning and from
34 healthy controls (Table 2).cortisol/cortisone or (THF  5-THF)/THE ratios in
patients on hemodialysis (Fig. 1).
Analytical procedure
Conjugated and unconjugated fractions of THE, THF
METHODS
5-THF, F and E were quantified by gas chromatogra-
Subjects phy/mass spectrometry (GC/MS) according to the method
initially developed by Shackleton for urine [24, 25]. WithInformed consent was obtained from all subjects and
the study complied with the local ethical guidelines. some modifications, this method also was applied to
plasma and dialysate samples. Briefly, to 1.5 mL of urine,Blood and dialysate samples were obtained from 12 pa-
tients (8 males and 4 females) on chronic hemodialysis 1 mL of plasma or 50 mL of dialysate, 2.5 g of medroxy-
progesterone was added as a recovery standard and the(HD) for more than one year (Table 1). In addition to
the drugs given in Table 1, the patients were on other sample extracted with 10 mL dichloromethane for 15
minutes on a rotator. After centrifugation and separationdrug therapies commonly used in chronic renal failure
including phosphate and potassium binders, as well as of the phases, the organic layer containing the unconju-
gated steroids was evaporated under a stream of nitrogenvitamin D supplement and recombinant human erythro-
poietin (rhEPO). Hemodialysis machines (Miroclav, at room temperature. At this point, the internal stan-
dards (5-androstane-3,17-diol, stigmasterol andBaxter, Ettlingen, Germany) were calibrated to different
blood flow and to a fixed dialysate flow of 500 mL/min cholesteryl butyrate, 2.5 g each) were added to the
extracts and methyloxime-trimethylsilyl ether deriva-(Table 1). Capillary hemofilters (Fresenius Medical
Care, Bad Homburg, Germany) with a polysulfone mem- tives were formed by derivatization (2 hours, 60C for
oxime formation, 16 hours, 100C for silylation). Thebrane were used for all dialysis sessions. The first blood
samples (10 mL) were collected in a potassium-EDTA samples were purified on a Lipidex 5000 column using
cyclohexane. This extract represented the unconjugatedMonovette syringe (Sarstedt, Germany) before the
start of the dialysis session in the morning. Additional fraction. To the water phase containing the conjugated
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Table 1. Patients and hemodialysis treatment parameters
Blood flow Dialysis time
Age Gender mL/min Filter h/session Diagnosis Drugs
EZ 70 M 400 HF 80S 3.30 GN
DI 43 M 400 HF 80S 3.00 RN Enalapril, atenolol
KL 45 M 400 HF 60S 3.30 GN
CF 72 M 400 HF 80S 3.30 ADKD Amlodipine
FN 65 M 380 HF 80S 3.00 DN Furosemide
WA 81 M 350 HF 80S 3.30 NA
HB 76 M 300 HF 80S 3.00 Unknown Furosemide
EM 72 M 300 HF 80S 4.00 Unknown
EM 44 F 400 HF 80S 3.00 PN
LM 62 F 300 HF 80S 3.00 PN Enalapril, furosemide
EB 71 F 300 HF 60S 3.45 IN Candesartan, atenolol, enalapril
Abbreviations are: GN, glomerulonephritis; RN, reflux nephropathy; ADKD, autosomal dominant polycystic kidney disease; DN, diabetic nephropathy; NA,
nephroangiosclerosis; GN, glomerulonephritis; PN, pyelonephritis; IN, interstitial nephropathy.
Table 2. Physical findings and cortisol metablites in plasma from 652, 605, 531 were monitored for THE, THF and 5-
patients on haemodialysis (HD) and healthy controls
THF, F and E, respectively. The derivatized samples
Patients were analyzed during a temperature program run (210 to
Parameters before HD Healthy controls
265C) over a 35-minute period. To quantify the samples,
Number men/women 63 (41/22) 34 (20/14) standard curves for THE, THF, 5-THF, F and E wereAge range 68 (30–91) 54 (24–78)
established ranging from 10 to 500 ng/mL. The lowestConjugated THE ng/mL 15484a 3014
Conjugated THF ng/mL 18691a 1810 detectable amounts were 500 pg for F and E, whereas
Conjugated 5-THF ng/mL 215116a 2618 50 pg of THE, THF and 5-THF could be detected.Unconjugated E ng/mL 136b 2312
Unconjugated F ng/mL 11537 9629 Coefficients of inter-day variation were 19%, 14% and
(5  THF  THF)/THE 3.01.2a 1.50.4 13% for conjugated THE, THF and 5-THF, respec-
THF/5-THF 1.00.7 0.80.3
tively, and 22% and 17% for unconjugated cortisol andF/E 9.35.3b 4.52.3
cortisone. Potential interference between different sam-Data are mean  SD. Abbreviations are in Table 1.
a P 	 0.00001 vs healthy controls ples was avoided by running a silylating reagent, N,O-
b P 	 0.0001 vs healthy controls
bis(trimethylsily)-trifluoroacetamide (Pierce, Rockford,
IL, USA) after each sample.
Calculation of metabolite clearancessteroids, 2.5 g of medroxyprogesterone was added as
a recovery standard. Plasma proteins were precipitated during hemodialysis
with 5 mL of methanol. After centrifugation, the super- Population pharmacokinetic models were used to cal-
natant was transferred into a new tube and dried under culate intradialytic clearance from plasma and dialysate
a stream of nitrogen. Conjugated steroids of dialysate concentrations of THE, THF and 5-THF [26–28].
samples were extracted with Sep Pak C18 cartridges Plasma and dialysate data were fitted to a one-compart-
(Waters, Milford, MA, USA), recovered with 5 mL of ment model assuming a constant metabolite production
methanol and dried under a stream of nitrogen. The prior to the dialysis procedure and allowing for individ-
samples were reconstituted in 0.1 mol/L acetate buffer,
ual alterations of the metabolite production rate during
adjusted to pH 4.6 and enzymatically hydrolyzed with
the dialysis session. No improvement of the model was12.5 g of powdered Helix pomatia enzyme (Sigma
observed when metabolite clearance estimates were re-Chemical Co., St. Louis, MO, USA) and 12.5 L of
lated to the prescribed BUN filter clearances, calculated-glucuronidase/arylsulfatase (Roche Diagnostics, Basel,
from the type and size of the filter and the blood andSwitzerland). The free steroids were recovered by Sep
dialysate flow rates during the dialysis session. AllowingPak C18 cartridge extraction. The subsequent steps were
different metabolite production rates for males and fe-the same as for the unconjugated steroids.
males significantly improved the fit of the model for 5-Samples were analyzed by selected ion monitoring on
THF with no effect on the fit of the models for THE ora Hewlett-Packard gas chromatograph 6890 equipped
THF. The final models to estimate intradialytic metabo-with a mass selective detector 5973, an autoinjector and
lite clearance values therefore did not relate clearancea HP 1MS capillary column of 15 m, 0.25 mm internal
values to prescribed small solute clearance values, butdiameter and 0.25 m film thickness (Hewlett Packard,
allowed for the determination of gender-specific metabo-Wilmington, DE, USA). One characteristic ion was cho-
sen for each metabolite being measured. Masses 578, lite production rates.
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Statistical methods
NONMEM version V (Nonlinear Mixed Effects Mod-
eling; NONMEM Project Group, University of Califor-
nia, San Francisco, CA, USA) [29, 30] on a DEC Alpha
3000–400 running Digital UNIX version 4.0F (digital
Equipment Corporation, Maynard, MA, USA) was used
for the population pharmacokinetic calculation of me-
tabolites clearances. The final models were fitted by first
order conditional estimation (FOCE) [29]. Results are
given as mean ( SD) unless indicated differently.
RESULTS
Cortisol and cortisone metabolites in plasma before
hemodialysis treatment
The plasma concentrations of conjugated THE, THF
and 5-THF in 63 patients and 34 volunteers are given
as a function of age in Figure 2. No significant correlation
was found between age of the patients and accumulation
of these metabolites. The mean concentrations in plasma
of THE, THF and 5-THF were higher in patients before
hemodialysis than in healthy controls (Table 2 and Fig.
2). Lower mean cortisone concentrations were found in
patients on dialysis than in controls, whereas the cortisol
concentrations were not different between the two
groups (Table 2 and Fig. 3).
The two parameters, considered to reflect 11-HSD2
activity, that is, the ratio of cortisol to cortisone (F/E)
and the ratio of their corresponding metabolites (5-
THF  THF)/THE (Fig. 1) were significantly higher in
patients on dialysis than in healthy controls (Table 2
and Fig. 4). The ratio of THF/5-THF was not different
between the two groups (Table 2 and Fig. 4).
Impact of dialysis treatment on cortisol and cortisone
metabolites in plasma
To analyze the impact of dialysis treatment on steroid
metabolites, plasma concentrations were analyzed in 11
patients before and after hemodialysis treatment and
compared with 12 age- and sex-matched controls (Table
3). The mean concentrations of the conjugated fraction
Fig. 2. Concentrations of conjugated THE (A), THF (B) and 5-THFof THE, THF and 5-THF in plasma were more than (C) in plasma of uremic patients (; N 
 63) and healthy controls (;
five times increased in the 11 patients before dialysis N 
 34) as a function of age. The individual values were determined
by GC/MS. Blood was obtained from patients in the morning beforewhen compared with their matched controls (Table 3).
the start of the dialysis session.At the end of the dialysis session, the mean concentra-
tions of all three metabolites THE, THF and 5-THF
decreased by a factor of 3 whereas the concentrations
of cortisol and cortisone remained unchanged. Similarly,
sate measured. In Table 4, the loss of these metabolitesthe steroid ratios reflecting 11-HSD2 activity, (5-
in the dialysate is given as amount of steroid lost duringTHF  THF)/THE, and F/E remained elevated after
a session or as amount lost in dialysate/day. The latterhemodialysis treatment (Table 3).
parameter is relevant for comparison with the amount
Cortisol and cortisone metabolites in dialysate of steroid metabolites excreted in urine/day in healthy
and urine controls. Table 4 reveals that the excretion of cortisol
(F) and 5-THF in urine from controls matched theIn the 11 patients described in Table 1, the dialysate
was collected and the amount of metabolites in the dialy- values found in the dialysate from the patients. The
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Fig. 3. Concentrations of unconjugated cortisol (A) and cortisone (B)
in plasma of uremic patients (; N 
 63) and healthy controls (; N 

34) as a function of age. The concentration of cortisone was below the
detection limit (	500 pg) in 2 patients.
amount of THE and THF recovered in urine was higher
in volunteers than in patients.
The intradialytic clearance of THE, estimated from
the population pharmacokinetic model was 268 mL/min
(17%; population mean, coefficient of variation), with
an intraindividual random variability of 45% (Fig. 5).
The estimated intradialytic clearances of 5-THF and
THF were 126 mL/min (13%) and 164 mL/min (28%)
with random variabilities of 51% and 44%, respectively.
Fig. 4. Ratio of cortisol metabolites in plasma of uremic patients (;
N 
 63) and healthy controls (; N 
 34) as a function of age. (A) TheDISCUSSION
ratio 5-tetrahydrocortisol  tetrahydrocortisol)/tetrahydrocortisone
In the past, the identification of cortisol metabolites (5-THF  THF)/THE); (B) the ratio between cortisol (F) and corti-
sone (E); and (C) the ratio between tetrahydrocortisol (THF) and 5-that accumulate in renal failure has been hampered by
tetrahydrocortisol (5-THF). The ratios of (5-THF THF)/THE andanalytical problems including isolation, separation and F/E are increased in uremic patients (P 	 0.0001).
detection of the various steroids in plasma and diluted
dialysate samples. We report here the first, to our knowl-
edge, GC/MS analysis of plasma and dialysate after parti-
and dialysate, a prerequisite for determining hemodialy-tioning conjugated and unconjugated fractions. By tak-
sis clearance of these steroids.ing advantage of the seminal work of Shackleton in the
Plasma concentrations of THE, THF and 5-THFfield of steroid profiling in biological fluids by GC/MS
were increased in patients on hemodialysis, whereas their[24, 25], it was possible to establish standard curves for
parent compounds cortisol and cortisone were normaleach steroid and obtain satisfactory accuracy for the de-
tection of these defined cortisol metabolites in plasma and decreased, respectively. This suggests that a reduced
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Table 3. Cortisol metabolites in plasma from patients on vant for the glucocorticoid-driven colonic potassium se-
hemodialysis (HD) and sex- and age-matched healthy controls
cretion in patients with end-stage renal diseases [32].
Patients (N 
 11) The enzyme 11-HSD2 exhibits a cell specific constitu-Controls
(N 
 12) Before HD After HD tive expression in mineralocorticoid target tissues, such
as epithelial cells from the colon and the renal corticalConjugated THE ng/mL 3110 154101a 4627d
Conjugated THF ng/mL 188 16688b 5228d collecting tubule, where its primary function is to protect
Conjugated 5-THF ng/mL 2815 20694b 7952d the mineralocorticoid receptor from activation by 11-
Unconjugated E ng/mL 237 10.33.5 10.03.5
hydroxyglucocorticoids including cortisol [13, 14, 16, 22].Unconjugated F ng/mL 11422 15530 13551
(5-THF  THF)/THE 1.40.4 3.21.9c 3.31.5 Loss of function mutations or inhibition of 11-HSD2
THF/5-THF 0.70.2 1.00.6 0.80.4 allows glucocorticoids to promote renal sodium reten-
F/E 5.61.9 15.93.6c 13.84.5
tion and potassium excretion in the cortical collecting
Data are mean  SD. Abbreviations are in Table 1.
tubule with subsequent volume expansion, hypertensiona P 	 0.005 compared to healthy controls
b P 	 0.0005 compared to healthy controls and suppression of renin and aldosterone [14, 33]. Re-
c P 	 0.05 compared to healthy controls
duced activity of this enzyme is diagnosed in vivo byd P 	 0.005 compared to values before dialysis
increased ratios of (THF  5-THF)/THE or cortisol/
cortisone in urine or in plasma [14, 15, 24, 25, 34]. The
hypertension induced by a low activity of 11-HSD2 is of
elimination and not an enhanced formation accounts for the salt sensitive type [34]. With declining renal function,
the increased concentrations of THE, THF and 5-THF patients become salt sensitive. Thus, the question arises
in our patients, a conclusion supported by the known whether the diminished apparent activity of 11-HSD2
reduced plasma clearance of free 11-hydroxy-glucocor- seen in our patients contributes to the salt sensitivity in
ticoids such as cortisol or prednisolone in uremia [11, 12]. patients on dialysis. As mentioned above, the role of the
The total amount of THE plus THF plus 5-THF recov- 11-HSD2 is to protect the mineralocorticoid receptor,
ered per day in dialysate from hemodialysis patients was and this enzyme is coexpressed with mineralocorticoid
reduced by 50% compared with the amount found in receptors. Provided the disappearance of 11-HSD2 ac-
urine from matched controls (4107 vs. 7800g/day; Table tivity in cortical collecting duct parallels the disappear-
4), reflecting a reduced daily secretion rate of cortisol ance of mineralocorticoid receptors, it is safe to conclude
and/or elimination of the three metabolites by another that the diminished activity of 11-HSD2 in patients with
route than hemodialysis in our patients. Due to higher a diminished renal function is clinically irrelevant. This
ratios in plasma, the dialysate ratios of (THF  5- statement is probably correct for patients on hemodialy-
THF)/THE from the patients were higher than those in sis, but possibly not so for patients with moderately im-
the urine from the healthy volunteers (Fig. 4, Tables paired renal function, as presently there are no experi-
2 and 3). Thus, in patients on hemodialysis, not only mental data in those latter patients. With respect to
accumulation but also a different pattern of these metab- dialysis patients, we have evidence from a prospective
olites is observed. controlled study that inhibition of 11-HSD2 activity
The increased ratios of (THF  5-THF)/THE and does not increase blood pressure in these patients, pro-
of cortisol/cortisone point to a reduced activity of the vided the body weight remains stable [35].
enzyme 11-HSD2. This reduced activity can be attrib- The reduced concentration of cortisone in patients
uted either to the presence of endogenous or exogenous on dialysis deserves special consideration. We have re-
inhibitors or to a reduced number of cells expressing the cently shown in vitro that cortisone blocked aldosterone-
enzyme 11-HSD2. Although it is possible that some induced mineralocorticoid receptor activation by a strictly
inhibitors, including furosemide [31], might account for 11-HSD2–dependent mechanism [23], an observation
part of the diminished apparent activity of 11-HSD2 in line with the blunted aldosterone-dependent renal
in patients on hemodialysis, the main mechanism is cer- sodium retention in adrenalectomized rats given an 11-
tainly the reduced mass of the organ with the highest ketoglucocorticoid [36, 37]. Whether the reduced for-
expression of 11-HSD2, that is, the kidney. We have mation of cortisone in dialysis patients facilitates min-
previously administered glycyrrhetenic acid to seven an- eralocorticoid receptor activation in vivo is open to
uric patients on hemodialysis and observed an 80% in- speculation. Nevertheless, the reduced concentrations of
crease in the cortisol/cortisone ratio in plasma, a finding cortisone found in the present investigation together
that indicates the presence of apparent 11-HSD2 activ- with the above-mentioned observation suggests that not
ity in hemodialysis patients [32]. In terms of quantity, only increased concentrations of middle molecules (see
the colon is probably the second most important site of next paragraph) but, in addition, reduced concentrations
11-HSD2 expression in the human body after the kid- of metabolites produced by the kidney have to be taken
ney and might account for 11-HSD2 activity in dialysis into account in understanding the toxicity in patients
with chronic renal failure.patients. The activity of 11-HSD2 appears to be rele-
N’Gankam et al: Cortisol metabolites and hemodialysis 1865
Table 4. Cortisol metabolites in dialysate from patients with chronic renal failure (N 
 11)
and in urine from sex- and age-matched controls (N 
 12)
Amount in dialysate/session Amount in dialysate/day Amount in urine/day
THE lg 31421561 1571815 41631359a
THF lg 2482944 1240472 22761125b
5-THF lg 25921962 1296981 1361763
F lg 21279 10639 9554
(5-THF  THF)/THE 1.70.8 1.70.8 0.90.2c
Values are given as mean  SD. Abbreviations are in Table 1.
a P 	 0.0005 compared to amount in dialysate per day
b P 	 0.05 compared to amount in dialysate per day
c P 	 0.005 compared to amount in dialysate per day
Fig. 5. Measured (dots) and predicted (line)
mean population concentrations of (A) tetra-
hydrocortisone (THE), (B) 5-tetrahydrocor-
tisol (5-THF) and (C) tetrahydrocortisol
(THF) in plasma during dialysis treatment.
Time 0 indicates the start of dialysis.
It is well recognized that substances are retained dur- treatment. Third, increased concentrations of the re-
agents should be related to specific uremic symptomsing uremia and many of these are partially removed by
extracorporeal therapy. The middle molecule hypothesis that should disappear when the concentrations are re-
duced. Thus far, this has not been shown for THF, 5-proposes that molecules within the range 300 to 12,000
D are inadequately removed by hemodialysis [4, 5]. The THF and THE. Some of the uremic symptoms including
osteopenia, abnormal fat distribution or enhanced pro-steroid molecules studied in the present investigation
fall within the range of those middle molecules. More tein metabolism fit into the list of those observed in
subjects with high glucocorticoid concentrations [8–10].middle molecules are removed by dialyzers containing
membranes with a larger pore size—as was the case in Therefore, a rational focus of future research would be
to establish a relationship between the steroid concentra-our patient cohort—than by dialyzers with a small pore
size [6]. Nevertheless, as clearly shown in our investiga- tions found in the present investigation and these symp-
toms. The final prerequisite for the definition of a uremiction, even treatment with large pore size dialyzers does
not normalize the concentrations of THF, 5-THF and toxin according to Bergstro¨m and Furst is evidence for
metabolic alterations and/or organ dysfunction in healthyTHE at the end of the dialysis session, indicating that
hemodialysis is not sufficient to remove all the steroid animals comparable to symptoms observed in uremic
patients after the administration of the putative toxinmetabolites accumulated during the interdialysis period
or produced during the dialysis treatment. [7]. Such studies have to be performed with the steroid
metabolites considered in the present investigation.In terms of criteria for uremic toxins, THF, 5-THF
and THE fulfill some, but not all, of the criteria proposed In conclusion, the present investigation demonstrates
first, that the concentrations of THF, 5-THF and THEby Bergstro¨m and Furst [7]. First, the compound should
be chemically identifiable in a specific manner. This is are increased and those of cortisone decreased in uremic
patients on hemodialysis, and second, that dialysis treat-now the case for our steroid metabolites. Secondly,
plasma and tissue levels should be higher in uremic pa- ment does not normalize the concentrations of these
cortisol metabolites. In patients on hemodialysis, the ra-tients than in healthy controls, even after hemodialysis
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